MK-677 (Ibutamoren) and Cannabis: The Interaction Profile Women Actually Need

What Is MK-677 and Why Are Women Using It?

MK-677 (ibutamoren) is a non-peptide ghrelin receptor agonist that tells the pituitary gland to release growth hormone (GH). Unlike injectable GH, it is taken by mouth, which is why it circulates in wellness and anti-aging communities as a supposedly convenient GH booster. It is not approved by the FDA for any medical use. It is sold as a "research chemical" and frequently mislabeled as a SARM (selective androgen receptor modulator), which it is not. The FDA has issued multiple warnings about MK-677 in consumer products, noting these compounds carry "potentially life-threatening" risks.

Women across several life stages are drawn to MK-677 for different reasons.

Who Is Using MK-677 and Why

Women in their reproductive years sometimes encounter MK-677 in fitness and body-composition spaces, where it is marketed for lean muscle gain and faster recovery. Women in perimenopause or post-menopause are increasingly exploring it for bone density and sleep quality, two areas where declining estrogen causes measurable problems. Women with PCOS sometimes ask about it because of the overlap between GH axis dysregulation and androgen excess, though no trials support this use.

The appeal is real. A randomized controlled trial in older adults published in the Journal of Clinical Endocrinology and Metabolism showed that 25 mg of ibutamoren daily for two years significantly increased IGF-1 levels and improved bone mineral density. However, that trial population was predominantly male and elderly, meaning findings cannot be directly transferred to women across the reproductive spectrum.

The WomanRx life-stage framework for evaluating MK-677 use looks like this: the younger you are and the more intact your estrogen signaling, the more MK-677 may disrupt your natural GH pulsatility without adding meaningful benefit. The closer you are to or past menopause, the more relevant the bone and sleep data becomes, but the metabolic risks (insulin resistance, fluid retention, increased cortisol) carry greater weight because estrogen is no longer providing its baseline insulin-sensitizing protection.

How MK-677 Works in the Female Body

MK-677 binds the ghrelin receptor (GHSR-1a) in the hypothalamus and pituitary. This stimulates GH pulses and downstream production of insulin-like growth factor 1 (IGF-1) from the liver. In premenopausal women, GH secretion is already higher than in men, partly driven by estrogen's ability to amplify GH pulse amplitude. Research published in the Journal of Clinical Endocrinology and Metabolism confirms that estrogen enhances pituitary GH secretion in women by reducing IGF-1 negative feedback. Adding exogenous GH secretagogue stimulation on top of an already estrogen-primed axis may over-stimulate GH without proportional IGF-1 response. After menopause, GH pulse amplitude falls and IGF-1 declines, so the rationale for secretagogue use shifts.

MK-677 also raises cortisol concentrations. A study in Endocrinology showed ghrelin receptor activation stimulates ACTH and cortisol release, which is relevant for any woman managing stress-related HPA dysfunction, which is common in perimenopause and in PCOS.

What Cannabis Does to Hormones and Metabolism

Cannabis affects far more than mood. The two primary cannabinoids, THC (delta-9-tetrahydrocannabinol) and CBD (cannabidiol), act on the endocannabinoid system (ECS), which is deeply woven into reproductive, metabolic, and stress physiology. The ECS in women is not the same as in men.

Endocannabinoid System and Female Hormones

Estrogen upregulates cannabinoid receptor 1 (CB1) density and sensitivity. This means women, particularly in the follicular phase when estrogen peaks, may feel stronger psychoactive effects from THC than men or than they themselves feel mid-cycle or post-menopause. Research published in Neuropsychopharmacology found that estrogen modulates CB1 receptor signaling, creating a sex-specific response profile to exogenous cannabinoids. Clinically, this means the same cannabis dose can hit harder at different points in your cycle.

Cannabis and Blood Glucose

THC acutely lowers fasting insulin and improves insulin sensitivity in short-term studies, but chronic heavy use is associated with increased rates of insulin resistance and metabolic syndrome. A cross-sectional analysis from NHANES data published in the American Journal of Medicine found current cannabis users had lower fasting insulin and smaller waist circumference compared with never-users, but this finding does not establish causation and does not apply to heavy or daily use. The picture inverts with chronic use.

MK-677, by contrast, reliably impairs insulin sensitivity. The two-year ibutamoren trial in JCEM documented significant increases in fasting blood glucose and insulin levels at the 25 mg dose. Combining a compound that consistently worsens glucose regulation with one that may acutely perturb it in unpredictable directions is a metabolic gamble.

Cannabis and the HPA Axis

Acute THC exposure activates the HPA axis and raises cortisol in occasional users. Chronic use blunts cortisol response over time. MK-677 raises cortisol through ghrelin receptor stimulation. The combined effect on cortisol across different use patterns is not studied in women, but the mechanistic concern is real: cortisol excess drives visceral fat, disrupts sleep architecture, and worsens insulin resistance. All three are problems MK-677 users are usually trying to fix.

The Direct Interaction Profile: What Happens When You Combine Them

No published clinical trial has examined the combination of MK-677 and cannabis in any population, female or male. Everything below is mechanistic reasoning and extrapolation from separate compound data. This is a genuine evidence gap. Women have been historically under-represented in clinical trials of both investigational compounds and cannabinoids, so be skeptical of anyone claiming certainty about this combination.

Appetite and Weight

Both MK-677 and cannabis independently stimulate appetite. Ghrelin receptor agonism directly triggers hunger signaling in the hypothalamus. THC activates CB1 receptors in the same hypothalamic regions, amplifying orexigenic (hunger-promoting) signaling. Used together, these appetite signals may stack. Women already struggling with PCOS-related weight management or perimenopausal metabolic changes should weigh this carefully.

Sedation and Sleep Architecture

MK-677 increases slow-wave sleep (SWS), the deep restorative stage when most GH is released. The original ibutamoren phase I/II data showed a 50% increase in SWS in healthy young men. Cannabis, particularly high-THC strains, also promotes sleep onset but suppresses REM sleep and may reduce overall sleep quality with regular use. The combination could produce excessive sedation the same evening while degrading long-term sleep quality, particularly for women who rely on MK-677's SWS benefit as a primary goal.

Metabolic Risk Stacking

This is the interaction that concerns clinicians most. MK-677 causes dose-dependent insulin resistance. Cannabis acutely disrupts glucose regulation in unpredictable ways depending on use frequency, THC content, and individual metabolic baseline. In perimenopause, where insulin sensitivity already declines as estrogen falls, adding two compounds that both perturb glucose metabolism is a meaningful risk. Women with PCOS, who already carry elevated risk for type 2 diabetes, are particularly vulnerable. ACOG's clinical guidance on PCOS highlights the importance of metabolic surveillance in affected women, and neither MK-677 nor cannabis is part of any PCOS treatment guideline.

CYP450 and Pharmacokinetic Interaction

MK-677 is metabolized primarily by CYP3A4. CBD is a known inhibitor of multiple CYP450 enzymes, including CYP3A4 and CYP2C19. Research in Cannabis and Cannabinoid Research confirmed CBD's inhibitory effects on CYP3A4 at concentrations achievable with standard doses. If CBD inhibits CYP3A4, MK-677 clearance may slow, raising plasma concentrations beyond the intended dose. This is not theoretical. It is the same mechanism that causes CBD to interact with warfarin and certain antiepileptics. No pharmacokinetic trial has measured this specific interaction, but the mechanism is established for each compound independently.

Hormonal Disruption in Women

Cannabis use is associated with disrupted LH pulsatility and altered menstrual cycle timing. A study in Obstetrics and Gynecology found that women who used cannabis had higher rates of menstrual cycle irregularity compared with non-users. MK-677's effect on LH in women is understudied. Because GH and IGF-1 interact with ovarian steroidogenesis, adding a GH secretagogue to an already hormonally disrupted system (perimenopause, PCOS, or postpartum recovery) carries unknown risks.

Pregnancy, Lactation, and Contraception

MK-677 is contraindicated in pregnancy. There are no human safety data. Animal reproductive toxicology data are not publicly available through regulatory submissions because this compound never reached clinical trial phases requiring them. Do not take MK-677 if you are pregnant, trying to conceive, or not using reliable contraception.

Cannabis is independently contraindicated in pregnancy. The American College of Obstetricians and Gynecologists explicitly states there is no known safe amount of cannabis use during pregnancy, citing associations with preterm birth, low birth weight, stillbirth, and long-term neurodevelopmental effects in offspring.

Cannabis transfers into breast milk. A study in Pediatrics using sensitive LC-MS/MS detection found THC in breast milk samples for up to six days after a single use. The AAP and ACOG both recommend avoiding cannabis during lactation. MK-677's lactation transfer has not been studied. Given the absence of any safety data and the biological plausibility that a GH secretagogue could alter neonatal GH axis development, MK-677 should be avoided during breastfeeding.

If you are in perimenopause and still ovulating irregularly, contraception remains necessary. MK-677 does not provide contraception. Cannabis does not provide contraception. Women using MK-677 who could become pregnant should use a reliable method.

Who This May Be Right For and Who Should Avoid It

Who Might Reasonably Consider MK-677 (Not Combined with Cannabis)

Post-menopausal women with documented low IGF-1, significant muscle loss (sarcopenia), or poor sleep architecture who cannot access growth hormone therapy through conventional endocrine channels sometimes ask about MK-677 as a stopgap. The evidence for bone density improvement is the most solid, drawn from the Nass et al. JCEM trial of ibutamoren in growth hormone-deficient adults, though this trial was in a different population than generally healthy post-menopausal women.

Women in this category should have baseline fasting glucose, HbA1c, and IGF-1 measured before starting, and monitored every three months if they proceed.

Who Should Avoid MK-677 Entirely

• Women who are pregnant, trying to conceive, or breastfeeding
• Women with prediabetes or type 2 diabetes (MK-677 worsens insulin resistance at therapeutic doses)
• Women with active or prior hormone-sensitive cancers (IGF-1 is a growth factor)
• Women with significant edema or carpal tunnel (fluid retention is a common side effect)
• Women under 25, where natural GH pulsatility is at its lifetime peak and additional stimulation offers no benefit

Adding Cannabis to MK-677: Who Should Specifically Not Do This

Any woman with PCOS and metabolic syndrome, any woman in perimenopause already experiencing insulin resistance, any woman with menstrual irregularity who has not yet identified its cause, and any woman taking medications that are CYP3A4-dependent (including many hormonal therapies, antifungals, and antiretrovirals) should not combine these compounds. The interaction potential is real even if the direct trial data does not yet exist.

What the Evidence Gap Means for You

Clinical honesty requires saying this directly: the combination of MK-677 and cannabis in women is essentially unstudied. Individual compound data in women is thin. The ibutamoren trials that exist were conducted mostly in men or in elderly mixed-sex populations. Cannabis research in women is growing but still sparse compared with male-dominant datasets. When a clinician tells you with confidence that this combination is safe or unsafe at a specific dose, ask them to cite the trial. That trial does not exist yet.

A 2021 review in the Journal of Women's Health documented persistent sex and gender gaps in clinical trials of investigational agents, particularly in the endocrinology and sports medicine spaces where compounds like MK-677 circulate. You deserve to know when the data that applies to you specifically has not been collected.

What you can reasonably conclude from existing mechanistic and indirect evidence: combining MK-677 and cannabis carries additive metabolic risk, unpredictable pharmacokinetic interactions via CYP3A4 inhibition by CBD, additive appetite stimulation, and overlapping HPA axis disruption. None of these interactions benefit the outcomes women typically pursue with either compound.

Monitoring If You Are Already Using MK-677

If you are currently using MK-677 and also using cannabis, these are the minimum monitoring parameters a clinician should check:

• Fasting glucose and HbA1c at baseline and every 3 months
• Fasting insulin and HOMA-IR to detect early insulin resistance
• IGF-1 (serum) to confirm GH axis response and avoid supraphysiologic levels
• Blood pressure (fluid retention from MK-677 can raise blood pressure)
• Menstrual cycle tracking if you are premenopausal or perimenopausal
• Cortisol (AM serum or 24-hour urine free cortisol) if you have symptoms of hypercortisolism

A fasting glucose above 100 mg/dL on MK-677 should prompt dose reduction or discontinuation. The 25 mg daily dose used in trials produced mean fasting glucose increases of approximately 0.3-0.4 mmol/L above baseline, a clinically meaningful shift in women who are already at the upper range of normal.